← Back to Clinical Trials
Recruiting NCT07517406

NCT07517406 Glycemic Markers for Predicting Gestational Diabetes in Pregnant Women With Previous Bariatric Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07517406
Status Recruiting
Phase
Sponsor Burak Deniz Aydoğdu
Condition Gestational Diabetes Mellitus (GDM)
Study Type OBSERVATIONAL
Enrollment 84 participants
Start Date 2026-02-01
Primary Completion 2027-12

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 50 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 84 participants in total. It began in 2026-02-01 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Gestational diabetes mellitus (GDM) is associated with significant maternal and fetal complications. The standard diagnostic test for GDM is the 75-gram oral glucose tolerance test (OGTT). However, pregnant women who have undergone bariatric surgery may not tolerate OGTT due to dumping syndrome and gastrointestinal side effects. This creates diagnostic challenges in this specific population. The aim of this prospective observational study is to evaluate whether routinely measured glycemic markers, including fasting blood glucose, postprandial blood glucose, HbA1c, and urinary glucose levels, can predict the development of gestational diabetes mellitus and related pregnancy complications in women with prior bariatric surgery. Pregnant women aged 18-50 years with a history of bariatric surgery will be enrolled and followed throughout pregnancy. The predictive value of glycemic markers for GDM, macrosomia, and polyhydramnios will be analyzed using multivariable logistic regression models. This study aims to provide alternative diagnostic approaches for GDM screening in pregnant women who are unable to tolerate OGTT and to contribute to improving maternal and perinatal outcomes in this growing patient population.

Eligibility Criteria

Inclusion Criteria * Pregnant women aged 18-50 years * Singleton pregnancy * History of bariatric surgery prior to pregnancy * Followed at Prof. Dr. Cemil Taşcıoğlu City Hospital, Department of Obstetrics and Gynecology * Availability of glycemic parameters during early pregnancy (≤14 weeks) and/or between 24 and 28 weeks of gestation (fasting plasma glucose, HbA1c, urine glucose, and/or OGTT results if tolerated) * Availability of sonographic and clinical follow-up data between 28 weeks of gestation and delivery (up to 40 weeks) Exclusion Criteria * Age \<18 years or \>50 years * Multiple pregnancy * Presence of known chronic systemic disease (e.g., pregestational diabetes or endocrine disorders) * Incomplete or missing clinical data

Contact & Investigator

Central Contact

Burak Deniz AYDOĞDU, MD

✉ burakd.1992@hotmail.com

📞 90 539-618-22-28

Principal Investigator

Burak Deniz AYDOĞDU, MD

PRINCIPAL INVESTIGATOR

Prof. Dr. Cemil Taşcıoğlu City Hospital, Department of Obstetrics and Gynecology

Frequently Asked Questions

Who can join the NCT07517406 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Gestational Diabetes Mellitus (GDM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07517406 currently recruiting?

Yes, NCT07517406 is actively recruiting participants. Contact the research team at burakd.1992@hotmail.com for enrollment information.

Where is the NCT07517406 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07517406 clinical trial?

NCT07517406 is sponsored by Burak Deniz Aydoğdu. The principal investigator is Burak Deniz AYDOĞDU, MD at Prof. Dr. Cemil Taşcıoğlu City Hospital, Department of Obstetrics and Gynecology. The trial plans to enroll 84 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology